Results 91 to 100 of about 1,955 (223)

Orthopedic Surgical Treatment of Patients with Tumor‐induced Osteomalacia Located in the Hip Bones: A Retrospective Analysis of 10 Years in a Single Center

Orthopaedic Surgery, Volume 16, Issue 8, Page 1871-1883, August 2024.
The location of the causative tumor in the hip bone is hidden and diverse, resulting in great challenges to endocrinologists and orthopedists. For the intraosseous tumor in hip bone, it may be quite difficult to remove the culprit tumor. In this situation, the proportion of recurrent/refractory cases has significantly increased, posing a huge challenge
Shuzhong Liu, Xi Zhou, Annan Liang, Jinyi Xing, Yong Liu, Jin Jin, Jianguo Zhang, Weibo Xia   +7 more
wiley   +1 more source

Burosumab vs conventional therapy in children with X-linked hypophosphatemia:results of the open-label, phase 3 extension period [PDF]

In a randomized, open-label phase 3 study of 61 children aged 1–12 years old with X-linked hypophosphatemia (XLH) previously treated with conventional therapy, changing to burosumab every 2 weeks (Q2W) for 64 weeks improved the phosphate metabolism ...
Biggin, Andrew, Chen, Angel, Cheong, Hae Il, Glorieux, Francis H, Gottesman, Gary S, Högler, Wolfgang, Imel, Erik A, Lawrence Merritt II, John, Munns, Craig F, Muroya, Koji, Namba, Noriyuki, Nilsson, Ola, Padidela, Raja, Perwad, Farzana, Pitukcheewanont, Pisit, Portale, Anthony A, Simmons, Jill H, Sochett, Etienne, Tanaka, Hiroyuki, Ward, Leanne M, Whyte, Michael P   +20 more
core   +1 more source

Kontraindikation von Crysvita�� (Burosumab)

, 2019
Crysvita® ist ein rekombinanter humaner monoklonaler IgG1-Antikörper, der spezifisch den bei Kindern mit X-chromosomaler Hypophosphatämie (XLH) im Übermaß gebildeten Fibroblasten-Wachstumsfaktor FGF23 blockiert, was zu einer Erhöhung der Serumphosphatwerte führt.
openaire   +2 more sources

Fibroblast growth factor 23 and calcium‐phosphate metabolism in relation to cardiovascular risk factors in patients with type 1 diabetes

Journal of Diabetes, Volume 16, Issue 6, June 2024.
Highlights Serum calcium, phosphate, calcium‐phosphate product and alkaline phosphatase levels were significantly higher in adult patients with type 1 diabetes (T1D) than in controls and were positively correlated to fibroblast growth factor 23 (FGF23) in patients with T1D. FGF23 was higher in current smokers than in nonsmokers with T1D. These findings
Stephanie Vermeulen, Mirjam E. A. Scheffer‐Rath, Martine T. P. Besouw, Amarens van der Vaart, Martin H. de Borst, Annemieke M. Boot   +5 more
wiley   +1 more source

Improvements with burosumab treatment in an early access programme for adults with X-linked hypophosphataemia: A case series of three patients

Bone Reports
X-linked hypophosphataemia (XLH) is a life-long phosphate-wasting disorder that causes skeletal deformities, pain, stiffness, and fatigue and impairs quality of life. Burosumab was approved for use in adults in 2020.
Julia Day, Chandrin Jayatilleke, Matthew Roy   +2 more
doaj   +1 more source

Diagnosis, treatment-monitoring and follow-up of children and adolescents with X-linked hypophosphatemia (XLH) [PDF]

, 2019
International ...
Högler, Wolfgang, Linglart, Agnes, Rothenbuhler, Anya, Schnabel, Dirk   +3 more
core   +3 more sources

Raquitismo hipofosfatêmico ligado ao X: uma nova mutação [PDF]

, 2020
Phosphopenic rickets may be caused by mutations in the PHEX gene (phosphate regulating endopeptidase homolog X-linked). Presently, more than 500 mutations in the PHEX gene have been found to cause hypophosphatemic rickets.
Abranches, M, Baptista, RB, Francisco, T, Freixo, JP, Maio, P, Mano, L, Rocha, S, Sousa, H   +7 more
core   +2 more sources

Unusual presentation of tumor‐induced osteomalacia mismanaged due to misdiagnosis: A literature review based on a case report

Clinical Case Reports, Volume 12, Issue 5, May 2024.
Key Clinical Message Tumor‐induced osteomalacia is a rare but potentially serious disease with nonspecific misguiding manifestations that can result in a wrong diagnosis and being treated for rheumatologic or other similar diseases. In patients with unexpected fractures, resistant musculoskeletal pains, and hypophosphatemia, this diagnosis should be ...
Mahdieh Fatollahzadeh, Hamid Reza Aghaei Meybodi, Hamid Pajavand, Moloud Payab, Mahbube Ebrahimpur, Pouya Ebrahimi   +5 more
wiley   +1 more source

Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis

Therapeutic Advances in Chronic Disease
Background: X-linked hypophosphatemia (XLH) is a rare, progressive disorder characterized by excess fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D synthesis.
Annemieke M. Boot, Gema Ariceta, Signe Sparre Beck-Nielsen, Maria Luisa Brandi, Karine Briot, Carmen de Lucas Collantes, Sandro Giannini, Dieter Haffner, Richard Keen, Elena Levtchenko, M. Zulf Mughal, Outi Mӓkitie, Ola Nilsson, Dirk Schnabel, Liana Tripto-Shkolnik, M. Carola Zillikens, Jonathan Liu, Alina Tudor, Francesco Emma   +18 more
doaj   +1 more source

Current situation and prospect for the diagnosis and treatment of pediatric critical rare diseases in China

Pediatric Investigation, Volume 8, Issue 1, Page 66-71, March 2024.
Children with critical rare diseases often have multiple organ dysfunction and high mortality. At present, there are some problems in the diagnosis and treatment of critical rare diseases of children in China, such as long diagnosis time, high misdiagnosis rate, limited treatment methods, and heavy disease burden.
Yingchao Liu, Suyun Qian
wiley   +1 more source